A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review

Yu Qing Cai,1,2 HangHu Zhang,1,4 Xiang Zhi Wang,1 ChengYun Xu,1 Yun Qi Chao,2 YingYing Shu,2 and Lan Fang Tang3

1Department of Pulmonology, Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, China, 2Department of Endocrinology, Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, China, 3Department of Pulmonology, Children’s Hospital of Zhejiang University School of Medicine & National Clinical Research Center, Hangzhou, China, and 4Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China

Major histocompatibility complex (MHC) II deficiency is a rare primary immunodeficiency disorder that is characterized by the deficiency of MHC class II molecules. The disease is caused by transcription factor mutations including class II transactivator (CIITA), regulatory factor X-5 (RFX5), RFX-associated protein (RFXAP), and RFXAP-containing ankyrin repeat (RFXANK), respectively. Mutations in the RFXANK gene account for >70% of all known patients worldwide. Herein, we reported a 10-month-old boy with MHC II deficiency caused by a novel mutation in the RFXANK gene (c.337 + 1G>C). The boy was admitted to the hospital due to pneumonia and diarrhea at 4 months of age. Genetic analysis revealed a novel homozygous mutation in the RFXANK gene, which derived from the c.337 + 1G>C heterozygous mutations in the RFXANK gene of his parents. The boy died 3 months after diagnosis. More than 200 cases have been reported, and a review of the literature revealed different mutation rates of 4 transcription factors in different countries or regions. This is the first case report of MHC II deficiency from East Asia. We also describe all gene mutations that cause MHC II deficiency and the epidemiology of MHC II deficiency with gene mutations in this paper.

Keywords. gene mutation; immunodeficiency disorder; infection; MHC II deficiency; RFXANK.

Major histocompatibility complex (MHC) II deficiency is a rare primary immunodeficiency disease that is characterized by the deficiency of MHC class II molecules. More than 200 cases have been reported in the literature. About two-thirds of the patients were reported from North African countries, which have a high prevalence of consanguineous marriages [1]. Although MHC II deficiency is regarded as less severe than severe combined immunodeficiency (SCID) according to the International Union of Immunological Societies classification criteria, patients usually exhibit clinical manifestations of typical combined immunodeficiency (CID) but not SCID [2, 3]. MHC II deficiency is characterized by an early onset of severe and recurrent infections, mainly of the respiratory and gastrointestinal tract, developmental delay, and early death [4]. Protracted diarrhea and recurrent pneumonia can be observed in almost all patients [2]. These patients are susceptible to a broad range of bacterial, viral, fungal, and protozoan infections, while cytomegalovirus (CMV), herpes simplex virus (HSV), Pneumocystis jirovecii, Salmonella, and Cryptosporidium species are the most common pathogens [3].

It is unique that MHC II deficiency exhibits the phenotypic manifestation of loss of molecular MHC II on the surface of specialized cells, while the mutated genes reside outside the MHC II locus [3]. The deficiency of MHC class II molecule, caused by transcription factor mutations, leads to impaired antigen presentation by HLA-DR, HLA-DQ, and HLA-DP molecules on antigen-presenting cells (APCs) such as dendritic cells and macrophages [5]. Moreover, transcription factor mutations could affect both the cell-mediated and humoral immunity due to defective CD4 T-cell development and a lack of Th-cell-dependent antibody production by B cells [6].

Different from the major histocompatibility complex I (MHC I) molecule expressed on almost all cells, the MHC II molecule is expressed on restricted cells like thymic epithelial cells and professional antigen-presenting cells or other types of cells stimulated by interferon-γ [7]. Besides the different expression loci, the expression of the MHC II gene is regulated by MHC II enhanceosome (a cell-specific multiprotein complex) [7]. Based on the experiment results of the isolation of the gene from the patients with MHC II deficiency, Reith et al. found 2 key regulatory factors that activate transcription of the genes encoding MHC II, class II transactivator (CIITA) and multiprotein RFX complex [8]. The RFX complex, which is composed of regulatory factor X-5 (RFX5), RFX-associated protein (RFXAP), and RFXAP-containing ankyrin repeat (RFXANK), binds directly to the promoters of MHC II genes and associates with other pleiotropic factors to form the MHC II enhanceosome [9]. Subsequently, due to the 4 different transcript factors, MHC II deficiency is divided into 4 groups from group A to D, which are CIITA, RFXANK, RFX5, and RFXAP, respectively [4].

Herein, we report on a Chinese patient with MHC II deficiency caused by a novel homozygous mutation in the RFXANK...
gene. We also detail a review of the literature on all gene mutations found in patients with MHC II deficiency.

**CASE REPORT**

A 7-month-old male Chinese boy was referred to our hospital because of cough and shortness of breath for 10 days. He was born at full term to healthy unrelated Chinese parents without family history of any genetic disorders. The perinatal course was uneventful. Peripheral blood cell counts in a local hospital showed a white blood cell count of \(25.84 \times 10^9/L\), neutrophil 42.8\%, lymphocyte 51.1\%, hemoglobin 119 g/L, thrombocyte \(325 \times 10^{12}/L\), and C-response protein (CRP) 1 mg/L. Chest x-ray showed multiple diffuse dense shadows in both lungs. He was treated with antibiotics and steroids. However, his condition exacerbated to severe pneumonia with the above treatments at the local hospital. Antibiotics and inhalation oxygen with face mask were given, and he was transferred to our hospital. In our hospital, his condition was exacerbated, with remarkably decreased oxygen saturation, and mechanical ventilation was given.

Laboratory evaluation exhibited positive viral testing for parainfluenza virus 3 (PIV3). Bronchial alveolar lavage sample tested negative for respiratory syncytial virus polymerase chain reaction (PCR), nasopharyngeal PCR, adenovirus PCR, and influenza virus PCR. Quantitative PCRs for hepatitis virus, *Treponema pallidum*, Epstein-Barr virus (EBV), and HIV were negative from blood. The bacterial and fungal cultures from lower respiratory samples revealed infection with *Ralstonia mannitolilytica* and *Stenotrophomonas maltophilia*. To further evaluate the pathogen, we did the pathogenic microorganism gene high-sequence test, which showed *Pneumocystis jirovecii* infection and *Stenotrophomonas maltophilia* infection. The CMV PCR was positive not only from blood, but also from urine, stool, and sputum. The immunologic evaluation suggested hypogammaglobulinemia with a low CD4+ cell percentage of only 6.47\%. Bone marrow biopsy was normal.

Flow cytometry for HLA class II expression was negative for HLA-DR on T cells, B cells, and monocytes. Whole-exome sequencing revealed that the patient had a homozygous c.337 + 1G>C mutation in the RFXANK gene. This mutation occurs in the first base of exon 5, which may cause a splicing mutation that induces a truncated protein. Both of his parents carried the heterozygous mutation c.337 + 1G>C in the RFXANK gene (Figure 1). The above results confirmed the diagnosis of MHC II deficiency. However, due to severe lung infections, the patient died after 3 months of treatment.

**CLINICAL REVIEW**

In this article, we report on a child referred to our hospital who developed progressive pneumonia, even with antibi-otic and steroid therapy. Laboratory examinations found that the patient had hypogammaglobulinemia with a low CD4+ lymphocyte percentage. *Pneumocystis jirovecii* infection was found in this patient. Ben-Mustapha et al. suggested that more than 90% of patients with MHC II deficiency will be infected with *Pneumocystis jirovecii*, which gave us a hint.

![Figure 1](image.png)

**Figure 1.** A novel homozygous mutation in the RFXANK gene (NM_003721; exon5; c.337 + 1G>C) was found that leads to a splicing mutation, which results in protein dysfunction. Sanger sequencing confirmed that the patient was homozygous and the parents (father and mother) were both heterozygous carriers for this mutation.
that the patient may have had CID because of MHC II deficiency [10]. So, we performed exome sequencing and flow cytometric evaluation of the MHC II molecule. As a result, we found a homozygous c.337 + 1G>C mutation in RFXANK in this patient, whose parents were carriers of a heterozygous mutation. The patient died 3 months after diagnosis. Our experience from the diagnosis and treatment of this patient suggests that if a patient is diagnosed with primary immunodeficiency (PID) and with several opportunistic infections, especially Pneumocystis jirovecii, it is best to undertake whole-exome sequencing and flow cytometric evaluation of the MHC II molecule to determine whether the PID is caused by the MHC II deficiency. Moreover, we found a novel RFXANK mutation that results in MHC II deficiency. At the same time, the homozygous mutations of the RFXANK gene were derived from the heterozygous mutation of his parents, who were not close relatives, which may imply that the rate of this kind of heterozygous mutation carrier is not low in Chinese people, even in East Asians.

**LITERATURE REVIEW**

MHC II deficiency is classified into 4 complementation groups, named by the order of their discovery according to MHC II molecule expression after pairwise fusion of different patient cell lines [3]. MHC II deficiency is divided into 4 groups, groups A to D, which are CIITA, RFXANK, RFX5, and RFXAP, respectively [4]. Group B MHC II deficiency is the most common, with more than half of the patients [11]. Besides the RFXANK gene mutation, most MHC II deficiency patients present with the context of consanguinity or ethnically similar communities, the majority in North Africa [12]. Nevertheless, it is interesting and unique that our patient had a homozygous c.337 + 1G>C mutation in the RFXANK gene given the parents’ ethnicity—Chinese. The parents of our patient are not closely related, which means that the heterozygous mutation in the RFXANK gene may be more widespread in the East Asian population than previously thought, considering that MHC II deficiency is a kind of autosomal recessive inheritance disease [7]. Ultimately, the mutation found in our patient leads to a splicing defect and nonfunctional RFXANK protein and prevents the transcription of the MHC II molecule, resulting in a severe immunodeficiency phenotype. Moreover, we carried out a systematic literature review on all reported patients with MHC II deficiency in PubMed with the keywords “MHC II deficiency” and “bare lymphocyte syndrome,” which is the former name of MHC II deficiency, up to April 2020. The data were extracted from those studies with gene mutation or ethnicity information for patients. Here, clinical data for each of the 4 different groups are presented in Tables 1–4, each containing information about the gene mutations and ethnicities of the patients.

**Epidemiology**

Our systematic literature review (Supplementary Table 1) revealed 238 patients with MHC II deficiency. With our present knowledge of MHC II deficiency disease and with the development of gene sequencing technology, patients who used to be diagnosed with PID would be further diagnosed as having MHC II deficiency. The geographical distribution of MHC II defects is mainly limited to areas with a high incidence of consanguineous marriages [13]. MHC II deficiency is more prevalent in North African countries or Mediterranean countries. Of the 178 patients with MHC II deficiency whose ethnicity is known, 117 (65.7%) come from North Africa and 152 (85.4%) from Mediterranean countries. Consanguineous marriages, which increase the incidence of autosomal recessive disorders due to the limited gene pool, are quite prevalent in these regions [14]. However, Group B MHC II deficiency is more concentrated in North African areas, while Group A seems to be more prevalent in European countries, and Group D is more prevalent in Asian countries (Supplementary Table 1). Such differences may be caused by the gene differences of the different races. More studies are needed to investigate the difference.

**Gene Mutation Analysis**

Due to the lack of unique clinical manifestations between MHC II deficiency and other immunodeficiency diseases, it is difficult for doctors to distinguish these 2 kinds of disease [13]. However, with gene sequencing technology, the list of mutations underlying MHC II deficiency is increasing. MHC II deficiency can be distinguished from PID by examination of the MHC II molecule on immune cells, or gene sequencing [3]. Gene sequencing can not only find the main deficiency-causing mutation, but also other mutations that may pose potential disease risk [15]. There were only 5 kinds of mutations in the CIITA gene reported before 2000, while the number reached 12 in 2018 [16]. Herein, we find a novel homozygous mutation in the RFXANK gene. Interestingly, the patient is a homozygous carrier of the c.337 + 1G>C mutation (Figure 1), with both parents showing a heterozygous configuration. This mutated allele may be widespread within the Chinese population considering the autosomal recessive inheritance of the MHC II deficiency. It is of great value to identify the genetic defects underlying MHC II deficiency for targeted gene therapy, which is a potential treatment.

The first discovered MHC II deficiency mutated gene was CIITA localized on chromosome 16 [17]. The N-terminal region of the CIITA acts as a transcriptional activator, while the C-terminal region provides MHC II promoter specificity [18]. The CIITA possesses 3 isoforms, all of which contain a leucine-rich region (LRR) participating in a protein–protein interaction. The LRR domain plays an important role in CIITA movement into the nucleus and in regulating its transactivation function [19]. Hanna and Etzioni reported in 2014 that there
were 9 mutations of the CIITA that induce MHC II deficiency disease [9]. Most of the mutations of the CIITA result in a premature stop codon, leading to a truncated protein or missense mutations, making for inactive proteins (Table 1). Nevertheless, we find that 13 mutations of the CIITA could account for Group A related to MHC II deficiency. Most defective CIITA proteins lose the ability to bind to the enhanceosome complex in the promoter of the MHC II gene due to a defective LRR region. Here, we study 16 (16/177) patients diagnosed with MHC II deficiency because of the CIITA gene mutation. There are 3 patients with the homozygous c.1256G>T (p. Glu381X) mutation and 3 with the homozygous c.1524T>C (p. L469P) mutation. The first mutation is found not only in European patients, but also in North African patients, while the other mutations were only found in Greek patients. Given the autosomal recessive inheritance of this disease, the CIITA mutation may be more prevalent in the European population, which is consistent with previous reports [8].

The key DNA binding component of the MHC II enhanceosome regulating the expression of MHC II genes is the RFX complex, which comprised of 3 proteins: RFXANK, RFX5, and RFXAP. The RFXANK gene consisting of 10 exons is located on the 19p12 locus [12]. The isoforms of RFXANK proteins depend on the number of ankyrin repeats, which are the crucial protein–protein interaction sites for the formation of the RFX complex [20]. Each repeat, composed of 2 antiparallel helices and a beta-hairpin, is stacked in a superhelical armament coupled with other repeats [21]. In addition, the RFXANK β-hairpin loops 1–3 are responsible for the binding of RFXANK to RFXAP. Mutations in the RFXANK gene in MHC II deficiency belong to group B, the largest group of the MHC II deficiency patients; 75.3% (131/174) of all known MHC II deficiencies with gene mutation information are defects in the RFXANK (Table 2). There are 19 different mutations that have been identified in patients with RFXANK mutations. The most frequent mutation is 752delG-25, which originated from an ancestor from the Maghreb (North Africa), leading to the formation of an mRNA lacking exons 5 and 6 [18]. The rest of the mutations are clustered in exons 5 to 9, a region that encodes ankyrin repeats, and are found in patients from different countries (Italy, Saudi Arabia, Iran, Kuwait, and Turkey). Most of the mutations result in protein lacking either some or all of the ankyrin repeats, causing truncated or inactive proteins. It is interesting that the 752delG-25 and IVS4 defects (IVS4 + 1G>C,

| Mutation of CIITA | Result | Case Number | Ethnicity | Author | Year of Publication |
|------------------|--------|-------------|-----------|--------|-------------------|
| Homozygous c.2436C>A | p. Cys812Ter | 1 | Indian | Aluri et al. | 2018 [32] |
| Homozygous c.929delA p. Asp310fs | P/S/T domain was impaired | 1 | Egyptian | El Hawary et al. | 2018 [1] |
| Homozygous c.3317 + 1G>A | - | 1 | Mexican-Iranian | Dimitrova et al. | 2014 [33] |
| Homozygous p. Glu381X | Nonsense mutation in exon 11, leading to loss of the C-terminal nuclear localization domain/ impaired binding of CIITA to enhanceosome | 1 | Austrian | Schmetterer et al. | 2010 [34] |
| Homozygous c.1256G>T (p. Glu381X) | Premature stop | 1 | Australian | Schmetterer et al. | 2010 [34–36] |
| | Premature stop | 1 | Austrian | Bontron et al. | 1997 |
| | | 1 | North African | Mannhalter et al. | 1991 |
| Heterozygous c.G2178A (p. Trp to X) Paternal allele: only silent mutations | | 1 | NC | Dziembowska et al. | 2002 [37] |
| Allele 1: del3003-3084 Allele 2: CATdel3193-5 | Allele 1: exon skipping between Leu964 and Asp991 (27 aa) | 1 | NC | Dziembowska et al. | 2002 [37] |
| No mutations in coding or noncoding regions | Probably mutated stabilizing region or regulatory sequence | 1 | NC | Dziembowska et al. | 2002 [37] |
| Homozygous c.1524T>C (p. L469P) | Missense mutation in N-terminal end of LRR motif, which is essential for CIITA activity | 3 | Greek | Wiszniewski et al. | 2001 [38] |
| Homozygous c. 84bp del 3265–3348 | Splice donor site mutation results in 28-aa truncated protein | 1 | Turkish | Peijnenburg et al. | 2000 [39] |
| Homozygous p. F961S | Missense mutation leading to an inactive protein | 1 | NC | Quan et al. | 1999 [40] |
| Homozygous c. 72bp del2932-3003 | Exon skipping -24-aa truncated protein | 1 | NC | Steimle et al. | 1993 [17] |

Abbreviations: aa, amino acid; CIITA, class II transactivator; LRR, leucine-rich region; NC, no comment.
IVS4 + 5G>A can be easily detected through RT-PCR, which might permit simple and early diagnosis for a vast number of RFXANK-mutative patients [22]. The patient described here is the first patient with c.337 + 1G>C destroying the splicing donor site of RFXANK belonging to the pathogenic very strong (PVS1) degree, according to the American College of Medical Genetics and Genomics [23], which may lead to a truncated RFXANK gene product.

All members of this RFX family share a common motif called the RFX DNA-binding domain (DBD) [24]. Previous experiments have found that RFXAP and RFX5 assemble in the cytoplasm before translocating to the nucleus, in which they constitute the full RFX complex with RFXANK [25]. The RFX5 is in locus 1q21 with 12 exon transcript and contains highly conserved DBDs, which bind the X box MHC II gene before transcription [26]. Moreover, the DBDs of the RFX5 are in the 90–166 residues and 407–614 residues [27]. Eleven mutations have been reported now (Table 3), and more than half of them lead to a premature stop codon before the second DBD region. It has been proven that the 187–265 residues comprise
the dimerization domain of RFX5 [24]. Except for the mutations destroying the DBD region of RFX5, there is 1 missense mutation in an Egyptian patient leading to the impaired dimerization of RFX5 [1].

RFXAP, a 3-exon gene localized on chromosome 13q14, contains 3 regions, which are rich in acidic amino acids (DE), glutamine (Q), and basic amino acids (RK) reminiscent of a nuclear localization signal [28]. Most of the MHC II deficiency patients categorized as group D have defects within the first exon of the RFXAP in a region spanning nucleotides 116–540, which affects the nuclear localization signal or the acidic DE domain [29]. Additionally, the C-terminal end of the associated protein

Table 3. The Mutation of the RFX5 of Patients With MHC II Deficiency

| Mutation of RFX5 | Result | Case Number | Ethnicity | Author | Year of Publication | Reference |
|------------------|--------|-------------|-----------|--------|---------------------|----------|
| Homozygous c.1154delT | p. Leu385TerfsTer33 | 1 | Indian | Aluri et al. | 2018 | [32] |
| Homozygous c.455G>T (p. Gly152Val) | DNA-binding domain destroyed | 1 | Egyptian | Rabab et al. | 2018 | [1] |
| Homozygous c.1161G>A | Oligomerization domain destroyed | 1 | Egyptian | Rabab et al. | 2018 | [1] |
| Homozygous c.715C>T | Dimerization domain destroyed | 1 | Egyptian | Rabab et al. | 2018 | [1] |
| Homozygous c.445G>A (p. R149Q) | Missense mutation in DBD leading to impaired DNA-binding ability | 2 | NC | Nekrep et al. | 2002 | [49] |
| Homozygous c. 1122 C>T (p. Q321X) | 320-aa truncated protein that still contains the DNA-binding domain but is inactive | 1 | Dutch-Indonesian | Peijnenburg et al. | 1999 | [50] |
| Homozygous c. 4ntdel 312–315 (CAAG)fsX403-405 | Splice acceptor site mutation leading to 82-aa truncated protein that lacks the DBD | 1 | Turkish | Peijnenburg et al. | 1999 | [51] |
| Homozygous c. 10ntdel259-268fsX334 | Mutation in splice donor site | 2 | NC | Villard et al. | 1997 | [52] |
| Allele 1: c. 5Nt del386–390 fsX410| Truncated nonfunctional protein | 1 | NC | Steimle et al. | 1995 | [53] |
| Homozygous c. 1032 >T (p. R>X) | Severely truncated protein | – | NC | Steimle et al. | 1995 | [53] |
| Homozygous c. 1378 C>G (p. P>R) | Severely truncated protein | – | NC | Steimle et al. | 1995 | [53] |

Abbreviations: aa, amino acid; DBD, DNA-binding domain; NC, no comment; RFX5, regulatory factor X-5.

Table 4. The Mutations of the RFXAP of Patients With MHC II Deficiency

| Mutation of RFXAP | Result | Case Number | Ethnicity | Author | Year of Publication | Reference |
|-------------------|--------|-------------|-----------|--------|---------------------|----------|
| Homozygous c.460-461insC | p. lys155GlnfsTer21 | 2 | Indian | Aluri et al. | 2018 | [32] |
| Homozygous c.709-1G>T | Splicing mutation | 1 | Indian | Aluri et al. | 2018 | [32] |
| Homozygous p. Tyr73X | The introduction of a premature stop codon in the DE region | 1 | Mexican | Michael et al. | 2015 | [54] |
| Homozygous c.323T>A in exon 1 | Premature stop codon (p. Leu108X) | 1 | Mexican | Caroline et al. | 2013 | [55] |
| Homozygous c. delG484fsX525 | Severely truncated and inactive protein of only 136-aa | 1 | Austrian | Klaus et al. | 2010 | [34] |
| | | 2 | North African | Fondaneche et al. | 1998 | [56] |
| | | 1 | Algerian | Villard et al. | 1998 | [57] |
| | | 1 | Moroccan | Durand et al. | 1997 | [28] |
| Homozygous 75bp insertion in 5-UTR | Transcriptional silence of RFXAP | 1 | Turkish | Van Eggermond et al. | 2008 | [31] |
| Homozygous c. 279C>G (p. Q>X) | 52-aa truncated protein | 1 | Turkish | Fondaneche et al. | 1998 | [56] |
| Homozygous c. 151ins7 (GCCGCCG) fs329X | 136-aa truncated protein | 2 | Druze | Fondaneche et al. | 1998 | [56] |
| Homozygous c. 279 C>G (p. Q>X) | 52-aa truncated protein | 1 | Turkish | Villard et al. | 1997 | [58] |

Abbreviations: aa, amino acid; RFXAP, regulatory factor-associated protein.
(140–243 residues), a conserved sequence of the RFXAP, is substantial for binding to DNA [30]. Nine different mutations are described in Table 4. More than half of the mutations induced a premature stop codon before the C-terminal binding of the RFXAP protein. Five of the 15 patients from North African countries possessed the same c. delG484fsX525 mutation. Thus, it is not unreasonable for us to presume the prevalence of this mutation in the North African region. Interestingly, a homozygous 75-bp insertion in the 5'-UTR mutation in the RFXAP was reported in a Turkish patient [31]. This mutation disrupts the promoter activity of the RFXAP through insertion of a 5-fold 15-bp repeat in the extreme 5' end of the 5'-UTR of RFXAP, which then prohibits RFXAP transcription. This rare mutation, outside the coding region of the RFXAP, reminds us that sometimes whole-exome sequencing is not sufficient to determine the mutation that caused the MHC II deficiency. Whole-genome sequencing would explain more gene mutation information, like the mutations in noncoding regions that affect gene expression.

CONCLUSIONS

Herein, we first describe a case of MHC II deficiency with a novel splicing mutation in the fifth exon of RFXANK in a Chinese patient, whose diagnosis was guided by the finding of *Pneumocystis jirovecii* infection. Through literature review, we found that there have been no cases of MHC II deficiency reported in China, or even in East Asian countries. Moreover, we found that the number of MHC II deficiencies has reached >200, and the mutation rates of the 4 transcription factors were different in different regions. Due to the rareness of the MHC II deficiency, we provided a review of the reported MHC II deficiency cases to help elucidate the spectrum of epidemiological and genetic characteristics of MHC II deficiency disease.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We want to thank the patients and their parents for allowing us to use the data.

Financial support. This work was supported by the National Natural Science Foundation (81170016 & 81470214) and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents (2016).

Patent consent. Consent was obtained from the parents, and the study was approved by the Ethical Committee of the Children's Hospital of Zhejiang University School of Medicine.

Potential conflicts of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. El Hawary RE, Mauracher AA, Meshaal SS, et al. MHC-II deficiency among Egyptians: novel mutations and unique phenotypes. J Allergy Clin Immunol Pract 2019; 7:856–63.
2. Tangye SG, Al-Herz W, Boussiba A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020; 40:24–64.
3. Hanna S, Ezetian A. MHC class I and II deficiencies. J Allergy Clin Immunol 2014; 134:269–75.
4. Iann SM, Anderson C, McNaughton P, et al. Improved transplant survival and long-term disease outcome in children with MHC class II deficiency. Blood. 2020; 135:954–73.
5. Waldburger JM, Masternak K, Muhlethaler-Mottet A, et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000; 178:148–65.
6. Sage AF, Murphy D, Maffia P, et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation 2014; 130:1363–73.
7. Nkerep N, Fontes JD, Geyer M, et al. When the lymphocyte loses its clothes. Immunity 2003; 18:453–7.
8. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001; 19:331–73.
9. Al-Herz W, Alsmadi O, Melhem M, et al. Major histocompatibility complex class II deficiency in Kuwait: clinical manifestations, immunological findings and molecular profile. J Clin Immunol 2013; 33:513–9.
10. Ben-Mustapha I, Ben Farhat K, Guirat-Dhouib N, et al. Clinical, immunological and genetic findings of a large Tunisian series of major histocompatibility complex class II deficiency patients. J Clin Immunol 2013; 33:865–70.
11. Abolnezhadhan F, Saeedi-Boroujeni A, Imamparast S. MHC class II deficiency with normal CD4+ T cell counts: a case report. Iran J Allergy Asthma Immunol 2018; 17:594–600.
12. Naamane H, El Maataoui A, Ailal F, et al. The 753delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr 2010; 169:1069–74.
13. Klein C, Lisowska-Grospiere B, LeDeste F, Fischer A, Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunological features, and outcome. J Pediatr 1993; 123:921–8.
14. Masternak N, Muhlethaler-Mottet A, Villard J, et al. Molecular genetics of the bare lymphocyte syndrome. Rev Immunogenet 2000; 2:267–82.
15. Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. New Engl J Med 2018; 379:1353–62.
16. Farrokhzad S, Shabani M, Aryan Z, et al. MHC class II deficiency: report of a novel mutation and special review. Allergol Immunopathol (Madrd) 2018; 46:263–75.
17. Steimle V, Otten LA, Zufferey M, et al. The 5'-UTR of the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds to the promoter without transactivating MHC II. Immunogenetics 2003; 57:135–46.
18. Djdjik R, Messouadini N, Tiahit A, et al. Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II deficiency. Allergy Asthma Clin Immunol 2012; 8:14.
19. Devaiah BN, Singer DS. CITA and its dual roles in MHC gene transcription. Front Immunol 2013; 4:476.
20. Wizniewski W, Fondaneche MC, Louise-Plence P, et al. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics 2003; 54:747–55.
21. Lemoine-Duménil AM, Barbouche MR, Vedrenne J, et al. Uncoordinated HLA-D subunits and MHC class II expression. J Immunol 1993; 140:968–73.
22. Prod'homme T, Dekel B, Barbieri G, et al. Splicing defect in RFXANK results of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Gene Med 2015; 17:405–24.
23. Briggs L, Laird K, Boss JM, Garvie CW. Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP. Proteins 2009; 76:655–64.
24. Nagarajan UM, Long AB, Harreman MT, Corbett AH, Boss JM. A hierarchy of nuclear localization signals governs the import of the regulatory factor X complex subunits and MHC class II expression. J Immunol 2004; 173:410–9.

NOVEL ID CASES • OFID • 7
26. Jabrane-Ferrat N, Nekre N, Tosi G, et al. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol 2002; 22:5616–25.

27. Claridge K, Leitenberg D, Loechelt B, et al. Major histocompatibility complex class II deficiency due to a novel mutation in RXANK in a child of Mexican descent. J Clin Immunol 2016; 36:4–5.

28. Durand B, Sperisen P, Emery P, et al. RXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997; 16:1045–55.

29. Garvie CW, Boss JM. Assembly of the RFX complex on the MHCII promoter: role of RXFAP and RXFB in relieving autoinhibition of RFX5. Biochim Biophys Acta 2008; 1779:797–804.

30. Long AB, Ferguson AM, Majumder P, et al. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression. Mol Immunol 2006; 43:395–409.

31. van Eggermond MC, Tezcan I, Heemskerk MH, van den EIJ P. Transcriptional silencing of RXFAP in MHC class II deficiency. Mol Immunol 2008; 45:2920–8.

32. Aluri J, Gupta M, Dalvi A, Mhatre S, et al. Clinical, immunological, and molecular findings in five patients with major histocompatibility complex class II deficiency from India. Front Immunol 2018; 9:188.

33. Dimitrova D, Ong PY, O’Gorman MR, Church JA. Major histocompatibility complex class II deficiency complicated by Mycobacterium avium complex in a boy of mixed ethnicity. J Clin Immunol 2014; 34:677–80.

34. Schmifterer KG, Seidel MG, Körmiocz U, et al. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discordant invariant chain expression levels. Int Arch Allergy Immunol 2010; 152:390–400.

35. Mannhalter JW, Wolf HM, Gadner H, et al. Cell-mediated immune functions in a patient with MHC class II deficiency. Immunol Invest 1991; 20:151–67.

36. Bontron S, Steimle V, Ucla C, et al. Novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet 1997; 99:541–6.

37. Dziembowska M, Fondaneche MC, Vedrenne J, et al. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics 2002; 53:821–9.

38. Wiszniewski W, Fondaneche MC, Le Deist F, et al. Mutation in the class II transactivator CIITA in a second patient from MHC class II deficiency complementation group B. Immunogenetics 1999; 51:493–501.

39. Peijnenburg A, Van den Berg R, Van Eggermond MJ, et al. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5. J Immunol 1999; 163:794–801.

40. Peijnenburg A, Van Eggermond MC, Van den Berg R, et al. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene. Immunogenetics 1999; 49:338–45.

41. Villard J, Reith W, Barras E, et al. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency. Hum Mutat 1997; 10:430–5.

42. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9:1021–32.

43. K ME, P ST. Type II bare lymphocyte syndrome: role of peripheral blood flow cytometry and utility of stem cell transplant in treatment. J Pediatric Hematol Oncol 2015; 37:e245–9.

44. Kienzler AK, Rizzi M, Reith M, Nutt SL, Eibel H. Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. J Allergy Clin Immunol 2013; 131:1689–95.

45. Fondaneche MC, Villard J, Wiszniewski W, et al. Genetic and molecular definition of complementation group D in MHC class II deficiency. Hum Mol Genet 1998; 7:879–85.

46. Villard J, Mach B, Reith W. MHC class II deficiency: definition of a new complementation group. Immunobiology 1997; 198:264–72.

47. Villard J, Lisowski-Grospiere B, van den EIJ P, et al. Mutation of RXFAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med 1997; 337:748–53.